Table 2.
Demographic and clinical characteristics of denosumab adherence versus non-adherence groups at 24 months (n = 28) a
| Characteristics | Denosumab treatment adherence at 24 months | p-value c | |
|---|---|---|---|
| Adherent group (n = 17) b | Non-adherent group (n = 11) b | ||
| Age (years), median (IQR) | 39.0 (36.0–43.3) | 39.0 (34.0–45.0) | 0.962 |
| Gender, male, n (%) | 15 (88.2) | 10 (90.9) | 1.000 |
| BMI (kg/m2), median (IQR) | 21.4 (19.2–24.7) | 19.0 (18.6–20.7) | 0.145 |
| Current smoking, n (%) | 6 (35.3) | 6 (54.5) | 0.441 |
| Prior AIDS diagnosis, n (%) | 4 (23.5) | 6 (54.5) | 0.125 |
| Time since diagnosis HIV (years), median (IQR) | 5 (1–10) | 1 (0–4) | 0.007 |
| CD4 cell count (cells/µL), median (IQR) | 534 (373–805) | 355 (149–827) | 0.158 |
| Time on antiretroviral therapy (years), median (IQR) | 4 (2–10) | 1 (1–3) | 0.005 |
| Denosumab treatment initiated before the COVID-19 pandemic, n (%) | 16 (94.1) | 6 (54.5) | 0.022 |
Abbreviations: AIDS acquired immunodeficiency syndrome, BMI body mass index, COVID-19 coronavirus disease 2019, HIV human immunodeficiency virus, IQR interquartile range
a Data are expressed as numbers and frequencies (%) or median values with interquartile ranges (IQRs)
b Adherence and persistence were evaluated for 24 months, excluding one case that did not reach 24 months after the commencement of denosumab treatment
c Fisher’s exact test was used for categorical data, and the Mann–Whitney U test was used for continuous data